Join to view full profile
1190 5th Ave# MountNew York, NY 10029
Phone+1 212-241-6756
Fax+1 212-423-0522
Dr. Schwartz is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1996 - 1999
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1992 - 1996
WashU MedicineClass of 1992
Certifications & Licensure
NY State Medical License 1993 - 2027
Publications & Presentations
PubMed
- 13 citationsGene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia.Miren Lasaga, Paula Río, Amaia Vilas-Zornoza, Nuria Planell, Susana Navarro
Haematologica. 2023-10-01 - 17 citationsImproved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposesJulián Sevilla, Susana Navarro, Paula Río, Rebeca Sanchez-Dominguez, Josune Zubicaray
Molecular Therapy. Methods & Clinical Development. 2021-09-10 - 7 citationsPreclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment.Susana Navarro, Oscar Quintana-Bustamante, Rebeca Sanchez-Dominguez, Sergio López-Manzaneda, Isabel Ojeda-Perez
Molecular Therapy. Methods & Clinical Development. 2021-09-10
Abstracts/Posters
- Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene...Jonathan D Schwartz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Hematopoietic Engraftment of Fanconi Anemia Patients through 3 Years after Gene TherapyJonathan D Schwartz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-IDecember 9th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
